- Home
- PIII vs XCUR Comparison
PIII vs XCUR Comparison
Compare PIII & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- XCUR
- Stock Information
- Founded
- PIII 2015
- XCUR 2011
- Country
- PIII United States
- XCUR United States
- Employees
- PIII N/A
- XCUR N/A
- Industry
- PIII Medical/Nursing Services
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- PIII Health Care
- XCUR Health Care
- Exchange
- PIII Nasdaq
- XCUR Nasdaq
- Market Cap
- PIII 28.6M
- XCUR 32.4M
- IPO Year
- PIII N/A
- XCUR N/A
- Fundamental
- Price
- PIII $8.38
- XCUR $4.00
- Analyst Decision
- PIII Strong Buy
- XCUR
- Analyst Count
- PIII 3
- XCUR 0
- Target Price
- PIII $17.50
- XCUR N/A
- AVG Volume (30 Days)
- PIII 7.0K
- XCUR 27.9K
- Earning Date
- PIII 11-11-2025
- XCUR 11-13-2025
- Dividend Yield
- PIII N/A
- XCUR N/A
- EPS Growth
- PIII N/A
- XCUR N/A
- EPS
- PIII N/A
- XCUR N/A
- Revenue
- PIII $1,461,823,000.00
- XCUR N/A
- Revenue This Year
- PIII N/A
- XCUR N/A
- Revenue Next Year
- PIII $9.46
- XCUR N/A
- P/E Ratio
- PIII N/A
- XCUR N/A
- Revenue Growth
- PIII 4.20
- XCUR N/A
- 52 Week Low
- PIII $5.80
- XCUR $1.91
- 52 Week High
- PIII $26.99
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- PIII 59.01
- XCUR 44.68
- Support Level
- PIII $8.46
- XCUR N/A
- Resistance Level
- PIII $8.90
- XCUR $4.12
- Average True Range (ATR)
- PIII 0.32
- XCUR 0.35
- MACD
- PIII -0.02
- XCUR -0.22
- Stochastic Oscillator
- PIII 49.07
- XCUR 64.62
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.